2005
DOI: 10.1016/j.transproceed.2005.09.191
|View full text |Cite
|
Sign up to set email alerts
|

Rapamycin in Lung Transplantation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2008
2008
2019
2019

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 18 publications
(3 citation statements)
references
References 6 publications
0
3
0
Order By: Relevance
“…However, because sirolimus initiation is usually delayed for 3 to 12 months after transplant, most sirolimus-treated patients must be identified from a follow-up immunosuppression record in the data set (occasionally available at 3 or 6 months but usually available only at 1 year after transplant or at death for patients who died within the first year). Because sirolimus use in the first year is sometimes for rescue rather than prophylactic use, commonly after the onset of chronic rejection or malignant disease 7,13,17 (which are both reported annually in the UNOS data set), patients experiencing chronic rejection or malignant disease in the first year would be more likely to receive sirolimus. To avoid this potential source of confounding, primary analyses were based on patients free of chronic rejection and malignant disease (and alive) at 1 year after transplant in all treatment groups.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…However, because sirolimus initiation is usually delayed for 3 to 12 months after transplant, most sirolimus-treated patients must be identified from a follow-up immunosuppression record in the data set (occasionally available at 3 or 6 months but usually available only at 1 year after transplant or at death for patients who died within the first year). Because sirolimus use in the first year is sometimes for rescue rather than prophylactic use, commonly after the onset of chronic rejection or malignant disease 7,13,17 (which are both reported annually in the UNOS data set), patients experiencing chronic rejection or malignant disease in the first year would be more likely to receive sirolimus. To avoid this potential source of confounding, primary analyses were based on patients free of chronic rejection and malignant disease (and alive) at 1 year after transplant in all treatment groups.…”
Section: Methodsmentioning
confidence: 99%
“…Potential benefits of sirolimus include multiple mechanisms for preventing chronic rejection 4,5,6,7 and anticancer 8,9,10,11 and antiaging 10,12 effects. Sirolimus has been an effective rescue therapy in lung transplantation after chronic rejection 7 or skin cancer 13 occurred with other immunosuppressants. The limited extent of prior studies 6,14,15,16 on prophylactic sirolimus use in lung transplantation has led to inconclusive findings, although results were favorable in most studies.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation